within Pharmacolibrary.Drugs.ATC.J;

model J06BB04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.9999999999999997e-06,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J06BB04</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Hepatitis B immunoglobulin (HBIG) is a human immune globulin containing a high titer of antibodies against hepatitis B virus (HBV). It is used for post-exposure prophylaxis to prevent hepatitis B infection, especially in individuals exposed to HBV (such as after perinatal exposure, needle stick injuries, or sexual exposure), and in combination with hepatitis B vaccine to prevent reinfection following liver transplantation. HBIG is approved and in current clinical use worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameter estimates primarily from healthy adult volunteers after intramuscular administration; in clinical use, parameters may vary depending on individual factors.</p><h4>References</h4><ol><li><p>Marzano, A, et al., &amp; Burra, P (2010). Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. <i>Minerva medica</i> 101(6) 373–383. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21196896/\">https://pubmed.ncbi.nlm.nih.gov/21196896</a></p></li><li><p>Filipponi, F, et al., &amp; Salizzoni, M (2010). Efficacy, safety, and pharmacokinetics of intramuscular hepatitis B immune globulin, Igantibe, for the prophylaxis of viral B hepatitis after liver transplantation. <i>Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver</i> 42(7) 509–514. DOI:<a href=\"https://doi.org/10.1016/j.dld.2009.09.005\">10.1016/j.dld.2009.09.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19828386/\">https://pubmed.ncbi.nlm.nih.gov/19828386</a></p></li><li><p>Hooman, N, et al., &amp; Rosenau, J (2008). Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. <i>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</i> 14(4) 435–442. DOI:<a href=\"https://doi.org/10.1002/lt.21343\">10.1002/lt.21343</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18383078/\">https://pubmed.ncbi.nlm.nih.gov/18383078</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J06BB04;
